Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Open Access
- 29 March 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 5 (6), 431-437
- https://doi.org/10.1016/s2213-8587(17)30104-3
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (grant P30DK020572)
- National Health and Medical Research Council of Australia (1006367, 358395, and 571281)
This publication has 16 references indexed in Scilit:
- Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes MellitusArchives of Internal Medicine, 2012
- Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholdsDiabetologia, 2011
- Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsBMJ, 2011
- Need for better diabetes treatment for improved renal outcomeKidney International, 2011
- Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trialsBMJ, 2011
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998